Euro vs US Dollar

Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.

Registrieren

QLGN Qualigen Therapeutics Inc

0,2875

0,0011 (0,38%)

Nach Börsenschluss

Zuletzt aktualisiert: 23:06:01

Verzögert um 15 Minuten

Form EFFECT - Notice of Effectiveness

Qualigen Therapeutics (NASDAQ:QLGN)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Click Here for more Qualigen Therapeutics Charts.

Qualigen Therapeutics (NASDAQ:QLGN)
Historical Stock Chart
Von Mai 2023 bis Mai 2024

Click Here for more Qualigen Therapeutics Charts.

News Qualigen Therapeutics Inc

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB
Dienstag 14 Mai 2024 (1 Woche vor) • Edgar (US Regulatory)

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
Samstag 4 Mai 2024 (3 Wochen vor) • Edgar (US Regulatory)

Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™
Dienstag 16 April 2024 (1 Monat vor) • GlobeNewswire Inc.

Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
Mittwoch 10 April 2024 (1 Monat vor) • GlobeNewswire Inc.

Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting
Dienstag 9 April 2024 (1 Monat vor) • GlobeNewswire Inc.

Form 8-K - Current report
Dienstag 27 Februar 2024 (3 Monate vor) • Edgar (US Regulatory)

Form 8-K - Current report
Donnerstag 22 Februar 2024 (3 Monate vor) • Edgar (US Regulatory)

Form 8-K - Current report
Donnerstag 7 Dezember 2023 (6 Monate vor) • Edgar (US Regulatory)

Form 8-K - Current report
Mittwoch 22 November 2023 (6 Monate vor) • Edgar (US Regulatory)

Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023
Dienstag 14 November 2023 (6 Monate vor) • GlobeNewswire Inc.

Form 8-K - Current report
Mittwoch 8 November 2023 (6 Monate vor) • Edgar (US Regulatory)

Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
Dienstag 7 November 2023 (7 Monate vor) • GlobeNewswire Inc.

Weitere Qualigen Therapeutics Inc News-Artikel

Health Care Select Sector

JP Morgan Chase

Euro vs US Dollar

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen